ArticleBioactive materials2021
A novel mechanism of inhibiting in-stent restenosis with arsenic trioxide drug-eluting stent: Enhancing contractile phenotype of vascular smooth muscle cells via YAP pathway.
Article in Bioactive materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 43 citations in OpenAlex.
- Mesenchymal stem cell membrane-coated kaempferol biomimetic nanoformulation for the treatment of atherosclerosis.APL bioengineering · 2026Article
- Dual-targeting phytochemicals Ergosterol and Quercetagetin implicate steroid metabolism-associated pathways in lung and liver cancer models.Frontiers in pharmacology · 2026Article
- Recent advances in surface functionalization of cardiovascular stents.Bioactive materials · 2025Review
- A Versatile Macroscale Platelet Membrane Coating: A Biomimetic Strategy to Balance Antithrombogenicity and Proendothelialization on Vascular Stents.Research (Washington, D.C.) · 2025Article
- Elevated Dickkopf 3 Promotes Abdominal Aortic Aneurysm Formation via Modulated Phenotype Switch of Vascular Smooth Muscle Cells.Research (Washington, D.C.) · 2025Article
- Recent advances of mechanosensitive genes in vascular endothelial cells for the formation and treatment of atherosclerosis.Genes & diseases · 2024Review
- Arsenic trioxide: applications, mechanisms of action, toxicity and rescue strategies to date.Archives of pharmacal research · 2024Review
- Sacubitril/valsartan inhibits the proliferation of vascular smooth muscle cells through notch signaling and ERK1/2 pathway.BMC cardiovascular disorders · 2024Article
- [Hot Topics and Emerging Trends in Mechanobiology Research].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Article
- Multilevel Assessment of Stent-Induced Inflammation in the Adjacent Vascular Tissue.ACS biomaterials science & engineering · 2023Article
- Comparative Study of Porous Iron Foams for Biodegradable Implants: Structural Analysis and In Vitro Assessment.Journal of functional biomaterials · 2023Article
- Structural and temporal dynamics analysis on drug-eluting stents: History, research hotspots and emerging trends.Bioactive materials · 2023Review
- Tuning macrophages for atherosclerosis treatment.Regenerative biomaterials · 2023Review
- Bioimpedance Sensing of Implanted Stent Occlusions: Smart Stent.Biosensors · 2022Article
- Two-stage degradation and novel functional endothelium characteristics of a 3-D printed bioresorbable scaffold.Bioactive materials · 2022Article
- FAK Activation Promotes SMC Dedifferentiation via Increased DNA Methylation in Contractile Genes.Circulation research · 2021Article
- miR-22 eluting cardiovascular stent based on a self-healable spongy coating inhibits in-stent restenosis.Bioactive materials · 2021Article
- Challenges and strategies forBioactive materials · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveArsenic trioxide (ATO or As METHODS AND
resultsThrough
conclusionsThe interaction of YAP with the ROCK pathway through ATO seems to mediate the contractile phenotype of VSMCs. This provides an indication of the clinical therapeutic mechanism for the beneficial bioactive effect of ATO-drug eluting stent (AES) on in-stent restenosis (ISR).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.